|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The role of chemokines in acute and chronic hepatitis C infection显示文摘丙肝在全球保健上强加重要负担。长期的感染与典型地在肝硬化,机关失败和癌症表明的肝的进步发炎被联系。由精致的避免策略的优点,丙肝病毒(HCV ) 作为一个坚持的人的病毒成功。它有一个非凡的能力破坏使它能建立长期的感染和联系的肝疾病的有免疫力的反应。Chemokines 是低分子的重量调停的趋化性的肽进纸巾的煽动性的房间和进 lymphatics 和外部血的背的招募。因此,他们对受动器和规章的有免疫力的房间的时间、空间的分发中央。在 chemokines 和他们的血缘的受体帮助之间的相互作用塑造有免疫力的反应因此,在感染的结果上有主要影响。然而, chemokines 包括 HCV 由病毒为调整代表一个目标。HCV 被知道并且可以因此由通过改变的白血球在 vivo 破坏有免疫力的反应启用它的幸存趋化性导致损害病毒的清理和长期的低档发炎的建立在 vitro 调制 chemokine 表示。在这评论,在尖锐、长期的 HCV 感染的 chemokines 的角色被描述,一个特别重音作为有免疫力的颠覆的一个工具放了在 chemokine 调整上。我们提供一在里面部分的深度讨论在调停由 chemokines 玩了肝的纤维变性当在预示的药为这些 chemoattractants 探讨潜在的应用时。 | Stephen Fahey Eugene Dempsey Aideen Long | 2014 | Cellular & Molecular Immunology2014，11，1： | 9 |
| 2 | The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson’s disease显示文摘Parkinson’s disease is the second most common neurodegenerative disorder;it affects 1%of the population over the age of 65.The number of people with Parkinson’s disease is set to rapidly increase due to changing demographics and there is an unmet clinical need for disease-modifying therapies.The pathological hallmarks of Parkinson’s disease are the progressive degeneration of dopaminergic neurons in the substantia nigra and their axons which project to the striatum,and the aggregation ofα-synuclein;these result in a range of debilitating motor and non-motor symptoms.The application of neurotrophic factors to protect and potentially regenerate the remaining dopaminergic neurons is a major area of research interest.However,this strategy has had limited success to date.Clinical trials of two well-known neurotrophic factors,glial cell line-derived neurotrophic factor and neurturin,have reported limited efficacy in Parkinson’s disease patients,despite these factors showing potent neurotrophic actions in animal studies.There is therefore a need to identify other neurotrophic factors that can protect againstα-synuclein-induced degeneration of dopaminergic neurons.The bone morphogenetic protein(BMP)family is the largest subgroup of the transforming growth factor-βsuperfamily of proteins.BMPs are naturally secreted proteins that play crucial roles throughout the developing nervous system.Importantly,many BMPs have been shown to be potent neurotrophic factors for dopaminergic neurons.Here we discuss recent work showing that transcripts for the BMP receptors and BMP2 are co-expressed with several key markers of dopaminergic neurons in the human substantia nigra,and evidence for downregulation of BMP2 expression at distinct stages of Parkinson’s disease.We also discuss studies that explored the effects of BMP2 treatment,in in vitro and in vivo models of Parkinson’s disease.These studies found potent effects of BMP2 on dopaminergic neurites,which is important given that axon degeneration is increasingly recognized as a key early event in Parkinson’s disease.Thus,the aim of this mini-review is to give an overview of the BMP family and the BMP-Smad signalling pathway,in addition to reviewing the available evidence demonstrating the potential of BMP2 for Parkinson’s disease therapy. | Susan R.Goulding Aideen M.Sullivan Gerard W.O’Keeffe Louise M.Collins | 2020 | Neural Regeneration Research2020，15，8： | 7 |
| 3 | Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease显示文摘Neuroprotection and neuroregeneration are two of the most promising disease-modifying therapies for the incurable and widespread Parkinson's disease. In Parkinson's disease, progressive degeneration of nigrostriatal dopaminergic neurons causes debilitating motor symptoms. Neurotrophic factors play important regulatory roles in the development, survival and maintenance of specific neuronal populations. These factors have the potential to slow down, halt or reverse the loss of nigrostriatal dopaminergic neurons in Parkinson's disease. Several neurotrophic factors have been investigated in this regard. This review article discusses the neurodevelopmental roles and therapeutic potential of three dopaminergic neurotrophic factors: glial cell line-derived neurotrophic factor, neurturin and growth/differentiation factor 5. | Shane V.Hegarty Gerard W.O’Keeffe Aideen M.Sullivan | 2014 | Neural Regeneration Research2014，9，19： | 6 |
| 4 | Neurotrophic factor therapy for Parkinson's disease: past, present and future显示文摘One of the greatest unmet needs in the treatment of Parkinson’s disease(PD)is a disease-modifying therapy,which can halt the ongoing degeneration of dopaminergic neurons that is characteristic of this disorder.Current therapies focus on managing symptoms,rather than on addressing their cause.Promising candidates for disease-modifying therapies are the dopaminergic neurotrophic factors(NTFs).NTFs are | Aideen M.Sullivan Gerard W.O'Keeffe | 2016 | Neural Regeneration Research2016，11，2： | 2 |
| 5 | Multi-center evaluation of oxidation-reduction potential by the MiOXSYS in males with abnormal semen显示文摘According to the World Health Organization(WHO),oxidative stress(OS)is a significant contributor to male infertility.SeminalOS can be measured by a number of assays,all of which are either costly or time sensitive and/or require large semen volume andcomplex instrumentation.One less expensive alternative is to quantify the oxidation-reduction potential(ORP)with the MiOXSYS.In this international multi-center study,we assessed whether ORP levels measured by the MiOXSYS could distinguish semensamples that fall within the 2010 WHO normal reference values from those that do not.Semen samples were collected from 2092patients in 9 countries;ORP was normalized to sperm concentration(mV/10^6 sperm/ml).Only those samples with a concentration>1×10^6 sperm ml1 were in eluded.The results showed that 199 samples fell within the WHO no rmal refere nee range while theremaining 1893 samples did not meet one or more of the criteria.ORP was negatively correlated with all semen parameters(P <0.01)except volume.The area under the curve for ORP was 0.765.The ORP cut-off value(1.34 mV/10^6 sperm/ml)was able todifferentiate specimens with abnormal semen parameters with 98.1%sensitivity,40.6%specificity,94.7%positive predictivevalue(PPV)and 66.6%negative predictive value(NPV).When used as an adjunct to traditional semen analysis,ORP levels mayhelp identify altered functional status of spermatozoa caused by OS in cases of idiopathic male infertility and in male partners ofcouples sufferi ng recurre nt pregna ncy loss,and thereby directi ng these men to relevant medical therapies and lifestyle modificati ons. | Ashok Agarwal Manesh Kumar Panner Selvam Mohamed Arafa Hiroshi Okada Sheryl Homa Aideen Killeen Basak Balaban Ramadan Saleh Abdullah Armagan Shubhadeep Roychoudhury Suresh Sikka | 2019 | Asian Journal of Andrology2019，21，6： | 2 |
| 6 | Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo显示文摘 | Jens S Aideen S Martina B | 2000 | J Neurosci2000，20，23： | 1 |
| 7 | Neurotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinsons disease显示文摘 | Fiona MH Daniel JC Aideen MS | 2004 | Experimental Neurology2004，185，： | 1 |
| 8 | Do we need a new vaccine to control the re-emergence of pertussis?显示文摘 | Kingston H.G. Mills Pádraig J. Ross Aideen C. Allen Mieszko M. Wilk | 2014 | Trends in Microbiology2014，，2： | 1 |
| 9 | The influence of microglia on the pathogenesis of Parkinson's disease 显示文摘 | Caitriona ML-S Aideen MS Yvonne MN | 2009 | Prog Neurobiol2009，89，3： | 1 |
| 10 | Correlation of sonographic findings and outcome in necrotizing enterocolitis显示文摘 | Cicero T. Silva Alan Daneman Oscar M. Navarro Aideen M. Moore Rahim Moineddin J. Ted Gerstle Ashok Mittal Mary Brindle Monica Epelman | 2007 | Pediatric Radiology2007，，： | 1 |
| 11 | Ventral midbrain neural stem cells have delayed neurogenic potential in vitro显示文摘 | Shane V. Hegarty Katie Spitere Aideen M. Sullivan Gerard W. O’Keeffe | 2013 | Neuroscience Letters2013，，： | 1 |
| 12 | Mutations in the Gene Encoding IFT Dynein Complex Component WDR34 Cause Jeune Asphyxiating Thoracic Dystrophy显示文摘 | Miriam Schmidts Julia Vodopiutz Sonia Christou-Savina Claudio R. Cortés Aideen M. McInerney-Leo Richard D. Emes Heleen H. Arts Beyhan Tüysüz Jason D’Silva Paul J. Leo Tom C. Giles Machteld M. Oud Jessica A. Harris Marije Koopmans Mhairi Marshall Nursel El | 2013 | The American Journal of Human Genetics2013，，5： | 1 |
| 13 | Metabolic engineering to increase isoflavone biosynthesis in soybean seed显示文摘 | Oliver Yu June Shi Aideen O. Hession Carl A. Maxwell Brian McGonigle Joan T. Odell | 2003 | Phytochemistry2003，，7： | 1 |
| 14 | l H-MRS spectroscopi charac- teristics of kernicterus : a possible metabolic signature 显示文摘 | Oakden WK Aideen M Moore | 2005 | AJNR2005，26，： | 1 |
| 15 | Targeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's disease显示文摘Introduction:Parkinson’s disease(PD)is a chronic,age-related neurodegenerative disorder that affects 1–2%of the population over the age of 65.PD is characterised by the progressive degeneration of nigrostriatal dopaminergic(DA)neurons.This leads to disabling motor symptoms,due to the striatal DA denervation.Despite decades of research, | Shane V.Hegarty Aideen M.Sullivan Gerard W.O'Keeffe | 2017 | Neural Regeneration Research2017，12，11： | 0 |
| 16 | Growth differentiation factor 5:a neurotrophic factor with neuroprotective potential in Parkinson’s disease显示文摘Parkinson’s disease is the most common movement disorder worldwide,affecting over 6 million people.It is an age-related disease,occurring in 1%of people over the age of 60,and 3%of the population over 80 years.The disease is characterized by the progressive loss of midbrain dopaminergic neurons from the substantia nigra,and their axons,which innervate the striatum,resulting in the characteristic motor and non-motor symptoms of Parkinson’s disease.This is paralleled by the intracellular accumulation ofα-synuclein in several regions of the nervous system.Current therapies are solely symptomatic and do not stop or slow disease progression.One promising disease-modifying strategy to arrest the loss of dopaminergic neurons is the targeted delivery of neurotrophic factors to the substantia nigra or striatum,to protect the remaining dopaminergic neurons of the nigrostriatal pathway.However,clinical trials of two well-established neurotrophic factors,glial cell line-derived neurotrophic factor and neurturin,have failed to meet their primary end-points.This failure is thought to be at least partly due to the downregulation byα-synuclein of Ret,the common co-receptor of glial cell line-derived neurorophic factor and neurturin.Growth/differentiation factor 5 is a member of the bone morphogenetic protein family of neurotrophic factors,that signals through the Ret-independent canonical Smad signaling pathway.Here,we review the evidence for the neurotrophic potential of growth/differentiation factor 5 in in vitro and in vivo models of Parkinson’s disease.We discuss new work on growth/differentiation factor 5’s mechanisms of action,as well as data showing that viral delivery of growth/differentiation factor 5 to the substantia nigra is neuroprotective in theα-synuclein rat model of Parkinson’s disease.These data highlight the potential for growth/differentiation factor 5 as a disease-modifying therapy for Parkinson’s disease. | Susan R.Goulding Jayanth Anantha Louise M.Collins Aideen M.Sullivan Gerard W.O’Keeffe | 2022 | Neural Regeneration Research2022，17，1： | 0 |
| 17 | The Epigenome as a therapeutic target for Parkinson's disease显示文摘Parkinsons disease(PD) is a common,progressive neurodegenerative disease characterised by degeneration of nigrostriatal dopaminergic neurons,aggregation of α-synuclein and motor symptoms.Current dopamine-replacement strategies provide symptomatic relief,however their effectiveness wear off over time and their prolonged use leads to disabling side-effects in PD patients.There is therefore a critical need to develop new drugs and drug targets to protect dopaminergic neurons and their axons from degeneration in PD.Over recent years,there has been robust evidence generated showing that epigenetic dysregulation occurs in PD patients,and that epigenetic modulation is a promising therapeutic approach for PD.This article first discusses the present evidence implicating global,and dopaminergic neuron-specific,alterations in the methylome in PD,and the therapeutic potential of pharmacologically targeting the methylome.It then focuses on another mechanism of epigenetic regulation,histone acetylation,and describes how the histone acetyltransferase(HAT) and histone deacetylase(HDAC) enzymes that mediate this process are attractive therapeutic targets for PD.It discusses the use of activators and/or inhibitors of HDACs and HATs in models of PD,and how these approaches for the selective modulation of histone acetylation elicit neuroprotective effects.Finally,it outlines the potential of employing small molecule epigenetic modulators as neuroprotective therapies for PD,and the future research that will be required to determine and realise this therapeutic potential. | Shane V.Hegarty Aideen M.Sullivan Gerard W.O'Keeffe | 2016 | Neural Regeneration Research2016，11，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员